S100A11 and hepatocellular carcinoma: Subsequent assays imply for the first time that S100A11 may present as an effective circulating biomarker for conjunctional use with AFP in HCC diagnosis, and S100A11 outperforms AFP in identifying whether HCC patients possess hematogenous metastasis or not.